A randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitis

Journal of Dermatological Treatment

Volumn 16, Issue 3, 2005, Pages 142-148

  Ling, Mark ^a   Gottlieb, Alice ^b   Pariser, David ^c   Caro, Ivan ^d   Stewart, Daniel ^e   Scott, Graham ^f   Abrams, Ken ^g  

^a MedaPhase Inc   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e Midwest Cutaneous Research Corp   (United States)

^f NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

^g NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Atopic dermatitis; BID; Corticosteroids; Eczema; Elidel; Four times daily; Pharmacokinetic; Pimecrolimus; PK; QID; Randomized controlled study; Skin atrophy; Systemic absorption; Twice daily

Indexed keywords

PIMECROLIMUS;

ADULT; ARTICLE; ATOPIC DERMATITIS; BLOOD SAMPLING; BURN; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERESTHESIA; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SCHOOL CHILD; SKIN ATROPHY; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; AREA UNDER CURVE; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; OINTMENTS; PROSPECTIVE STUDIES; SAFETY; STATISTICS, NONPARAMETRIC; TACROLIMUS; TREATMENT OUTCOME; UNITED STATES;

EID: 25444443426     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630510033159     Document Type: Article

References (26)

1. Grassberger M, Baumruker T, Enz A, Hiestand P, Hultsch T, Kalthoff F, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol. 1999;141:264-73.
2. Meingassner JG, Grassberger M, Fahrngruber H, Moore HD, Schuurman H, Stutz A. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Br J Dermatol. 1997;137:568-76.
3. Hultsch T, Muller KD, Meingassner JG, Grassberger M, Schopf RE, Knop J. Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner. Arch Dermatol Res. 1998;290:501-7.
4. Zuberbier T, Chong SU, Grunow K, Guhl S, Welker P, Grassberger M, et al. The ascomycin macrolactam pimecro-limus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils. J Allergy Clin Immunol. 2001;108:275-80.
5. Stuetz A, Grassberger M, Meingassner JG. Pimecrolimus (Elidel, SDZ ASM 981) - preclinical pharmacologic profile and skin selectivity. Semin Cutan Med Surg. 2001;20:233-41.
6. Queille-Roussel C, Paul C, Duteil L, Lefebvre MC, Rapatz G, Zagula M, et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol. 2001;144:507-13.
7. Wellington K, Jarvis B. Topical pimecrolimus: a review of its clinical potential in the management of atopic dermatitis. Drugs. 2002;62:817-40.
8. Meurer M, Folster-Holst R, Wozel G, Weidinger G, Junger M, Brautigam M, CASM-DE-01 study group. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology. 2002;205:271-7.
9. Wahn U, Bos JD, Goodfield M, Caputo R, Papp K, Manjra A, et al., Flare Reduction in Eczema with Elidel (Children) Multicenter Investigator Study Group. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics. 2002;110(1 Pt 1):e2.
10. Wellington K, Jarvis B. Spotlight on topical pimecrolimus in atopic dermatitis. Am J Clin Dermatol. 2002;3:435-8.
11. Harper J, Green A, Scott G, Gruendl E, Dorobek B, Cardno M, et al. First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dermatol. 2001;144:781-7.
12. Van Leent EJ, Graber M, Thurston M, Wagenaar A, Spuls PI, Bos JD. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol. 1998;134:805-9.
13. Lakhanpaul M, Davies T, Allen B, Stephenson T, Scott G, Ebelin ME, et al. Pimecrolimus (SDZ ASM 981) cream 1%: minimal absorption in infants with atopic dermatitis during long-term treatment. Ann Dermatol Venereol. 2002;129:18415.
14. Van Leent EJ, Ebelin ME, Burtin P, Dorobek B, Spuls PI, Bos JD. Low systemic exposure after repeated topical application of Pimecrolimus (Elidel), SD Z ASM 981) in patients with atopic dermatitis. Dermatology. 2002;204:63-8.
15. Billich A, Aschauer H, Stuetz A. Pimecrolimus permeates less through skin than topical corticosteroids. Ann Dermatol Venereol. 2002;29:1S693.
16. Billich A, Aschauer H, Stuetz A. Pimecrolimus (SDZ ASM 981) is more lipophilic and permeates less through skin than tacrolimus (FK506). Ann Dermatol Venereol. 2002;129:1S692.
17. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol. 2000;142:931-6.
18. Fukaya M. Why do patients with atopic dermatitis refuse to apply topical corticosteroids? Dermatology. 2000;201:242-5.
19. Fischer G. Compliance problems in paediatric atopic eczema. Australas J Dermatol. 1996;37(Suppl 1):S10-S13.
20. Paller AS, McAlister RO, Doyle JJ, Jackson A. Perceptions of physicians and pediatric patients about atopic dermatitis, its impact, and its treatment. Clin Pediatr (Phila). 2002;41:323-32.
21. Rajka G. Natural history and clinical manifestations of atopic dermatitis. Clin Rev Allergy. 1986;4:3-26.
22. Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol. 2001;10:11-18.
23. Gilbaldi M, Perrier F. Pharmacokinetics, 2nd ed. New York: Marcel Dekker; 2003.
24. Billich A, Aschauer H, Aszody A, Stuetz A. Pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharmacol. 2004;269:29-35.
25. Novartis Pharmaceuticals Corporation: Data on File.
26. Eichenfield LF, Lucky AW, Boguniewicz M, Langley RG, Cherill R, Marshall K, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol. 2002;46:495-504.